- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00213044
A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women
A Randomized, Controlled, Double-Blind, Cross-Over Trial of Safety, Effect on Genital Tract HIV Shedding, and Acceptability of Vaginal Use of Carraguard by HIV-Infected Women
Study Overview
Detailed Description
Carraguard™ (PC-515), the Population Council's lead candidate microbicide, was tested in a randomized, controlled trial in Chiang Rai, northern Thailand. Safety of daily product use determined by symptoms of irritation, effect on vaginal flora, vaginal epithelial disruption as determined by naked eye inspection (Day 7 and Day 14 of each arm) and colposcopic inspection on (Day 7), and other adverse effects, which may include UTI or other unforeseen problems (Day 7 and Day 14).
Genital tract HIV will be measured using samples collected by CVL (Day 7 and Day 14 of each arm) and vaginal swab (Day 7 and Day 14).
Product acceptability will be assessed through an interview-administered questionnaire once each study arm at the first follow-up visit (Day 7 of each arm), after using the product daily for 7 days.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chiang Rai, Thailand, 57001
- Chiang Rai Health Club
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-50 years
- Plan to stay in the Chiang Rai area for at least four months
- HIV-infected, confirmed by Elisa and Western Blot tests
- Either has 1) no current sex partner and is planning to be abstinent for the study duration, or 2) has only one, HIV-infected sexual partner1 who is 18 years or older and is willing to give informed consent for confirmatory HIV testing and for the participant=s enrollment in the study. Women who have a steady partner/husband who she will not see during the study period or with whom she is not sexually active will not be required to bring their partner to the clinic for HIV testing and informed consent.
- Willing and able to give informed consent
- Willing and able to comply with the study protocol, including being tested for HIV and undergoing repeated pelvic and colposcopic examinations
- Willing to have male partner asked for informed consent because he will be exposed to study product
- Regular menstrual cycles (defined as occurring every 3-5 weeks, lasting 3-5 days) for the prior 3 months; if have amenorrhea or if using depo-provera, participant must have no reported history of vaginal bleeding for the previous 3 months
- CD4 count < 5002
- Not currently taking antiretroviral medications3
- Documented Class I or Class II ("atypical cells seen, usually caused by inflammation") pap smear at screening for study participation
- In good health as determined by medical history, physical examination and results of any laboratory screening test, and the discretion of the clinical staff
- Able to achieve a score of 80% or better on true-false test of key study concepts. If women score less than 80% the first time they take the test, they may repeat the test at least one day later
Exclusion Criteria:
- CD4 count <50
- Pregnancy or desire to become pregnant in the next 3-4 months
- Delivery, miscarriage, or abortion within six weeks prior to study enrollment
- History of surgery on external genitalia, vagina or cervix in the month prior to study enrollment
- Existence of a clinically detectable genital abnormality, specifically warts or a congenital abnormality
- History of nonmenstrual vaginal bleeding with intercourse in past one month
- Current use of tampons, diaphragms, sponges, douching, or other intravaginal products. Women who are willing to abstain from using these products during the study will be included in the study.
- Concurrent participation in another trial of a vaginal product
- History of sensitivity or allergy to latex products (including gloves)
- Presence of epithelial disruption of the labia or genital mucosa visible to the naked eye at enrollment1
- Positive test for gonorrhea, chlamydial infection, trichomoniasis, or evidence of untreated syphilis (see section 5.19). Participants with positive tests must be treated and have a negative test of cure to be eligible for enrollment.1
- Positive tests for candidiasis or bacterial vaginosis (BV) and symptoms of vaginitis. Women may be enrolled after treatment if they are asymptomatic or have negative tests. Asymptomatic participants with positive tests for candidiasis or BV may be enrolled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety: irritation, effect on vaginal flora, vaginal epithelial disruption determined by visual inspection (Day 7, 14) and colposcopic inspection(Day 7); other adverse effects, which may include UTI or other unforeseen problems (Day 7, 14).
|
Genital tract HIV: measured using samples collected by CVL (Day 7, 14) and vaginal swab (Day 7, 14).
|
Acceptability: interview-administered questionnaire (Day 7).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Janneke van de Wijgert, PhD, Population Council
- Principal Investigator: Catherine McClean, Centers for Disease Control and Prevention
Publications and helpful links
General Publications
- Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH, Mock PA, Siraprapasiri T, Friedland BA, Kilmarx PH, Markowitz LE. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand. PLoS One. 2011;6(9):e14831. doi: 10.1371/journal.pone.0014831. Epub 2011 Sep 7.
- McLean CA, van de Wijgert JH, Jones HE, Karon JM, McNicoll JM, Whitehead SJ, Braunstein S, Achalapong J, Chaikummao S, Tappero JW, Markowitz LE, Kilmarx PH. HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand. AIDS. 2010 Mar 13;24(5):717-22. doi: 10.1097/QAD.0b013e328333bf89.
Study record dates
Study Major Dates
Study Start (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Population Council #316
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Carraguard (PC-515)
-
Population CouncilNational Institute of Allergy and Infectious Diseases (NIAID); United States... and other collaboratorsCompletedHIV Infections | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Neisseria GonorrhoeaeSouth Africa
-
Population CouncilUnited States Agency for International Development (USAID); Bill and Melinda...CompletedHIV Infections | Sexually Transmitted Diseases | AIDS | HIV SeroconversionSouth Africa
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand and other collaboratorsCompletedHIV Infections | Herpes Simplex | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Neisseria GonorrhoeaeThailand
-
Population CouncilMedical Research Council; Centers for Disease Control and PreventionCompleted
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand and other collaboratorsCompletedHIV Infections | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Nesseria GonorrheaThailand
-
TretheraRecruitingOncology | Solid Tumor, AdultUnited States
-
University Hospital, Basel, SwitzerlandCompletedHeart Failure; With DecompensationSwitzerland
-
Boehringer IngelheimCompleted
-
KU LeuvenAmsterdam UMC, location VUmc; Agentschap voor Innovatie door Wetenschap en... and other collaboratorsUnknownNursing Home Residents With Palliative Care NeedsBelgium
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completed